Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7Etanercept 6Methotrexate 3Adalimumab 3secukinumab 2Nivolumab 2sotrastaurin 1sodium luminolate 1ixekizumab 1deucravacitinib 1calcipotriene 1cabozantinib 1baricitinib 1apremilast 1abrocitinib 1Vitamin D 1Vaccines 1Specimen Handling 1Saline Solution 1Platinum Compounds 1Ipilimumab 1Herpes Zoster Vaccine 1Folic Acid 1Fish Oils 1Fatty Acids, Omega-3 1Exercise 1Eicosapentaenoic Acid 1Docosahexaenoic Acids 1Cholecalciferol 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Psoriasis × ixekizumab × Clear all
NCT01107457 2019-09-24

A Study in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed
142 enrolled 45 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡